- Home
- TACT vs AKTX Comparison
TACT vs AKTX Comparison
Compare TACT & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TACT
- AKTX
- Stock Information
- Founded
- TACT 1996
- AKTX N/A
- Country
- TACT United States
- AKTX United States
- Employees
- TACT N/A
- AKTX N/A
- Industry
- TACT Computer peripheral equipment
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- TACT Technology
- AKTX Health Care
- Exchange
- TACT Nasdaq
- AKTX Nasdaq
- Market Cap
- TACT 42.2M
- AKTX 35.7M
- IPO Year
- TACT 1996
- AKTX N/A
- Fundamental
- Price
- TACT $4.63
- AKTX $0.78
- Analyst Decision
- TACT Strong Buy
- AKTX Strong Buy
- Analyst Count
- TACT 1
- AKTX 2
- Target Price
- TACT $5.00
- AKTX $3.30
- AVG Volume (30 Days)
- TACT 68.6K
- AKTX 90.4K
- Earning Date
- TACT 11-06-2025
- AKTX 08-13-2025
- Dividend Yield
- TACT N/A
- AKTX N/A
- EPS Growth
- TACT N/A
- AKTX N/A
- EPS
- TACT N/A
- AKTX N/A
- Revenue
- TACT $47,949,000.00
- AKTX N/A
- Revenue This Year
- TACT $21.67
- AKTX N/A
- Revenue Next Year
- TACT $7.63
- AKTX N/A
- P/E Ratio
- TACT N/A
- AKTX N/A
- Revenue Growth
- TACT N/A
- AKTX N/A
- 52 Week Low
- TACT $3.12
- AKTX $0.57
- 52 Week High
- TACT $4.89
- AKTX $3.85
- Technical
- Relative Strength Index (RSI)
- TACT 64.75
- AKTX 39.91
- Support Level
- TACT $4.09
- AKTX $0.75
- Resistance Level
- TACT $4.76
- AKTX $0.89
- Average True Range (ATR)
- TACT 0.18
- AKTX 0.07
- MACD
- TACT -0.00
- AKTX 0.01
- Stochastic Oscillator
- TACT 80.64
- AKTX 65.72
About TACT TransAct Technologies Incorporated
Transact Technologies Inc develops and sells software-driven technology and printing solutions. The company's software is sold under BOHA, AccuDate, Epic, EPICENTRAL, Ithaca, and Printrex brand names. It also provides supplies and consumables used in the printing and scanning activities to restaurant and hospitality, banking, retail, casino and gaming, point of sale automation, lottery, medical, mobile, oil, and gas markets. Majority of the revenue is derived from the casinos and gaming industry followed by the Foodservice technology market. Its geographical segments are the United States and International, of which the majority of its revenue comes from the United States.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.